Long-term results from patients with episodic migraine show erenumab reduces migraine frequency and is well tolerated. Data from a trial conducted in the USA and Germany showed that results from a double-blind study were maintained in patients who completed at least 4 years of a 5-year open-label extension.
Vuoi saperne di più?
Accedi o registrati per accedere a tutti i contenuti di Neurodiem.
Hai già un account? Accedi
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.